Research > Cellular and molecular models of human pathologies

Molecular Oncology

The main interest of our laboratory is the study of molecular events underlying the oncogenic process, especially in colorectal, gastric and head-and-neck cancer. Gaining a deeper understanding of the molecular mechanisms responsible for the tumorigenic process is essential to improve the diagnosis and treatment of these patients. Also, we aim the identification of prognosis biomarkers to therapy in colorectal cancer to contribute to patients personalized medicine.


  • Head: Dr. Diego Arango del Corro
  • Senior Scientist: Dr. Águeda Martínez Barriocanal
  • Postdoctoral Researchers: Dr. Valentina Maggio
  • PhD Student: Estefania Anguita Espinosa
  • PhD Student: Li Jing
  • Laboratory Technician: Rocio Nieto Raya
  • Laboratory Technician: Elia García Vidal

Selected Publications

  1. RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. Rodrigues P, Macaya I, Bazzocco S, Mazzolini R, Andretta E, Dopeso H, Mateo-Lozano S, Bilić J, Cartón-García F, Nieto R, Suárez-López L, Afonso E, Landolfi S, Hernandez-Losa J, Kobayashi K, Ramón y Cajal S, Tabernero J, Tebbutt NC, Mariadason JM, Schwartz S Jr, Arango D. Nat Commun. 2014 Nov 21;5:5458. doi: 10.1038/ncomms6458
  2. Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Cartón-García F, Macaya I, de Marcondes PG, Anguita E, Masanas M, Jiménez-Flores LM, Martínez-Barriocanal Á, Nieto R, Segura MF, Schwartz S Jr, Mariadason JM, Arango D. Br J Cancer. 2018 Jan;118(1):106-116. doi: 10.1038/bjc.2017.420
  3. Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. Bazzocco S, Dopeso H, Carton-Garcia F, Macaya I, Andretta E, Chionh F, Rodrigues P, Garrido M, Alazzouzi H, Nieto R, Sanchez A, Schwartz S Jr, Bilic J, Mariadason JM, Arango D. Clin Cancer Res. 2015 Aug 15;21(16):3695-704. doi: 10.1158/1078-0432.CCR-14-2457
  4. Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Mateo-Lozano S, Bazzocco S, Rodrigues P, Mazzolini R, Andretta E, Dopeso H, Fernández Y, Del Llano E, Bilic J, Suárez-López L, Macaya I, Cartón-García F, Nieto R, Jimenez-Flores LM, de Marcondes PG, Nuñez Y, Afonso E, Cacci K, Hernández-Losa J, Landolfi S, Abasolo I, Ramón Y Cajal S, Mariadason JM, Schwartz S Jr, Matsui T, Arango D. Sci Rep. 2017 Mar 6;7:43702. doi: 10.1038/srep43702
  5. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Andretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, Bazzocco S, Bilic J, Rodrigues P, Nieto R, Landolfi S, Ramon Y Cajal S, Schwartz S, Brown A, Dopeso H, Arango D. Sci Rep. 2017 Feb 7;7:41576. doi: 10.1038/srep41576
  6. Myo5b knockout mice as a model of microvillus inclusion disease. Cartón-García F, Overeem AW, Nieto R, Bazzocco S, Dopeso H, Macaya I, Bilic J, Landolfi S, Hernandez-Losa J, Schwartz S Jr, Ramon y Cajal S, van Ijzendoorn SC, Arango D. Sci Rep. 2015 Jul 23;5:12312. doi: 10.1038/srep12312
  7. A molecular mechanism underlying genotype-specific intrahepatic cholestasis resulting from MYO5B mutations. Overeem AW, Li Q, Qiu YL, Carton-Garciá F, Leng C, Klappe K, Dronkers J, Hsiao NH, Wang JS, Arango D, van IJzendoorn SCD. Hepatology. 2019 Nov 21. doi: 10.1002/hep.31002
  8. Loss of MYO5B expression deregulates late endosome size which hinders mitotic spindle orientation. Leng C, Overeem AW, Cartón-Garcia F, Li Q, Klappe K, Kuipers J, Cui Y, Zuhorn IS, Arango D, van IJzendoorn SCD. PLoS Biol. 2019 Nov 4;17(11):e3000531. doi: 10.1371/journal.pbio.3000531
  9. Glucocorticoids and myosin5b loss of function induce heightened PKA signaling in addition to membrane traffic defects. Forteza R, Ahsan MK, Cartón-García F, Arango D, Ameen NA, Salas PJ. Mol Biol Cell. 2019 Dec 15;30(26):3076-3089. doi: 10.1091/mbc.E18-07-0415
  10. Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Ruiz de Porras V, Bystrup S, Cabrero-de Las Heras S, Musulén E, Palomero L, Alonso MH, Nieto R, Arango D, Moreno V, Queralt C, Manzano JL, Layos L, Bugés C, Martinez-Balibrea E. Cancers (Basel). 2019 Oct 11;11(10). pii: E1540. doi: 10.3390/cancers11101540
  11. DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, Mariadason JM. Sci Rep. 2018 Jan 29;8(1):1767. doi: 10.1038/s41598-018-20176-9
  12. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, Mariadason JM. Mol Cancer Ther. 2016 Jun;15(6):1217-26. doi: 10.1158/1535-7163.MCT-15-0724
  13. Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Gener P, Gouveia LP, Sabat GR, de Sousa Rafael DF, Fort NB, Arranja A, Fernández Y, Prieto RM, Ortega JS, Arango D, Abasolo I, Videira M, Schwartz S Jr. Nanomedicine. 2015 Nov;11(8):1883-92. doi: 10.1016/j.nano.2015.07.009
  14. The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner. Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM. J Biol Chem. 2015 Jun 19;290(25):15392. doi: 10.1074/jbc.A114.557546
  15. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM. Cancer Res. 2014 Jun 15;74(12):3238-47. doi: 10.1158/0008-5472.CAN-14-0013

Contact information

Diego Arango Del Corro

Diego Arango Del Corro